Gilead Sciences, Inc. (GILD) Shares Bought by TT International

TT International raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 88,014 shares of the biopharmaceutical company’s stock after purchasing an additional 2,074 shares during the quarter. Gilead Sciences makes up about 1.5% of TT International’s holdings, making the stock its 24th biggest holding. TT International’s holdings in Gilead Sciences were worth $6,236,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the business. Seizert Capital Partners LLC boosted its holdings in shares of Gilead Sciences by 4.6% during the 1st quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock valued at $42,964,000 after buying an additional 27,547 shares in the last quarter. Investment Centers of America Inc. boosted its holdings in shares of Gilead Sciences by 7.2% during the 1st quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock valued at $1,979,000 after buying an additional 1,958 shares in the last quarter. Fagan Associates Inc. boosted its holdings in shares of Gilead Sciences by 2.6% during the 2nd quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock valued at $2,341,000 after buying an additional 845 shares in the last quarter. Dai Ichi Life Insurance Company Ltd boosted its holdings in shares of Gilead Sciences by 7.6% during the 2nd quarter. Dai Ichi Life Insurance Company Ltd now owns 160,025 shares of the biopharmaceutical company’s stock valued at $11,327,000 after buying an additional 11,299 shares in the last quarter. Finally, Capital Asset Advisory Services LLC bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at $875,000. 76.23% of the stock is currently owned by institutional investors and hedge funds.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $82.56, for a total value of $6,054,372.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. In the last three months, insiders sold 494,999 shares of company stock valued at $37,404,139. 1.30% of the stock is owned by insiders.

A number of analysts have recently commented on the stock. ValuEngine upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 7th. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Zacks Investment Research cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Monday, September 11th. Vetr cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 price target on the stock. in a research note on Monday, September 4th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $83.00 price target (up previously from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Gilead Sciences has a consensus rating of “Buy” and an average price target of $85.11.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at $74.22 on Monday. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. The firm has a market capitalization of $96,951.29, a PE ratio of 7.75, a price-to-earnings-growth ratio of -1.24 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. During the same quarter in the previous year, the firm earned $2.75 EPS. Gilead Sciences’s revenue was down 13.2% on a year-over-year basis. equities analysts forecast that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.80%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is 23.69%.

ILLEGAL ACTIVITY WARNING: This report was originally reported by Week Herald and is the property of of Week Herald. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://weekherald.com/2017/12/11/gilead-sciences-inc-gild-shares-bought-by-tt-international.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply